Industry News
New protein points to possible Alzheimer’s cure
An 84-year old American Nobel Laureate has discovered a new protein which observers are saying may herald a completely new approach to treating Alzheimer’s disease. [ + ]
Halcygen reports maiden profit
Antibiotic developer Halcygen Pharmaceuticals today reported a maiden net profit of $3.25 million for the year ended June 30, 2010, largely driven by the company’s acquisition of Mayne Pharma International late last year from Hospira Inc. [ + ]
Feature: Diagnosing Darwin
In January last year, Dr John Hayman read a biography of Charles Darwin and became intrigued by Darwin’s almost lifelong battle with a chronic, relapsing illness. But now, Hayman, an Associate Professor in Monash University’s Department of Pathology, thinks he’s narrowed it down to a rare mitochondrial disorder inherited from his mother. [ + ]
Food security and anthrax protection
Food security and protection from anthrax contamination could be achieved using an antibacterial enzyme.
[ + ]Market report: Healthcare index outperforms wider market
The Australian stock market just clawed its way into positive territory today as investors defied the prevailing gloom surrounding the US economy, although it wasn’t enough to snap a three-week losing streak. [ + ]
China and India pharma companies driving M&A activity in Asia
A report by analyst group Datamonitor has identified China and India’s pharmaceutical industries as the ones to watch following a flurry of M&A activity over the last three years. [ + ]
Ramsay reports strong FY profit jump
Australia’s biggest healthcare provider Ramsay Healthcare this week reported a 21.9 percent jump in full-year net profit to $178.5 million. [ + ]
Under-arm license delivers maiden FY profit for Acrux
Testosterone booster Acrux this week stormed into the black for the first time, announcing a net profit of $46.6 million after earlier in the year signing one of the biggest ever multinational licensing deals for an Australian biotech. [ + ]
Mesoblast FY results reveal more red ink
Regenerative medicine specialists Mesoblast today reported a net loss of $14.8 million for the full year ended 30 June 2010, an increase on the previous year’s loss of $12.3 million. [ + ]
Mesoblast reports FY net loss of $14.8 million
Regenerative medicine specialists Mesoblast today reported a net loss of $14.8 million for the full year ended 30 June 2010. The company, noted, however that it had finished the year with cash reserves of $32.5 million, up from $16.5 million for the previous corresponding period. [ + ]
Mesoblast to buy US partner Angioblast
Regenerative medicine specialists Mesoblast announced this week that it has convened an extraordinary general meeting with shareholders to vote on the proposed acquisition of the company’s US partner Angioblast Systems. [ + ]
Cellestis reports FY net profit up 26 percent
Melbourne biotech Cellestis this week announced a full year net profit of $10.22 million, following strong growth in all of the company’s major markets. [ + ]
Researchers help gold industry face impurity challenge
As the more traditional gold deposits of the world become depleted, mining companies are facing the challenge of processing ores that contain higher concentrations of other metals.
[ + ]Market report: ASX down amid renewed global concerns while election hangs on a knife edge
The Australian stock market finished down today amid renewed concerns about the pace of the global economic recovery and as local investors await the outcome of tomorrow’s federal election, which has become too close to call. [ + ]